Proto Labs (NYSE: PRLB) corrects Q1 2026 GAAP EPS guidance in 8-K/A

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K/A

Rhea-AI Filing Summary

Proto Labs, Inc. filed an amended current report to correct a guidance figure in its previously issued outlook. The amendment clarifies that the company’s GAAP diluted earnings per share guidance range for the first quarter of 2026 is $0.18 to $0.26, instead of the $0.17 to $0.25 range originally described in the attached press release. No other aspects of the earlier report or the press release were changed, and the correction is described as a scrivener’s error.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/06/2026 - 02:50 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

Amendment No. 1

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 6, 2026

Proto Labs, Inc.

(Exact name of registrant as specified in its charter)

Minnesota

001-35435

41-1939628

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification Number)


5540 Pioneer Creek Drive Maple Plain, Minnesota						55359
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code:						(763) 479-3680


Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share	PRLB	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

This Current Report on Form 8-K/A (this “Amendment”) is being filed as an amendment to the Current Report on Form 8-K filed by Proto Labs, Inc. (the “Company”) with the Securities and Exchange Commission (“SEC”) on February 6, 2026 (the “Original Report”). The sole purpose for filing this Amendment is to correct a scrivener’s error in reporting the guidance range for GAAP diluted earnings per share (“EPS”) for the first quarter of 2026 as described in the press release furnished as Exhibit 99.1 to the Original Report (the “Original Exhibit 99.1”). The correct GAAP diluted EPS guidance range for Q1 2026 is $0.18 to $0.26, rather than the guidance range of $0.17 to $0.25 as reported in the Original Exhibit 99.1 (the “Specified Error”). This Amendment supplements the Original Report and should be read in conjunction with the Original Report. No other changes have been made to the Original Report or Original Exhibit 99.1 other than to correct the Specified Error, as described above and reflected below.


Item 2.02.			Results of Operations and Financial Condition.

On February 6, 2026, Proto Labs, Inc. issued a press release announcing its fourth quarter and full year 2025 financial results. The information set forth above under the heading “Explanatory Note” is incorporated by reference into this Item 2.02.

The information contained in Items 2.02 and 9.01 of this report is being “furnished” and not “filed” with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.


Item 9.01.			Financial Statements and Exhibits.

(d)Exhibits


104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Proto Labs, Inc.

Date:

February 6, 2026

By:

/s/ Daniel Schumacher

Daniel Schumacher

Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Proto Labs (PRLB) change in its latest 8-K/A filing?

Proto Labs corrected a guidance typo in its earlier report. The company clarified that GAAP diluted EPS guidance for Q1 2026 is $0.18–$0.26, not $0.17–$0.25, with no other changes made.

How did Proto Labs (PRLB) update its Q1 2026 EPS guidance range?

Proto Labs updated its Q1 2026 GAAP diluted EPS guidance range to $0.18–$0.26. The prior range of $0.17–$0.25 in the original press release was identified as a scrivener’s error and has now been corrected.

Does Proto Labs’ 8-K/A change any other 2025 or 2026 financial information?

No, the amendment only corrects the GAAP diluted EPS guidance range for Q1 2026. The company states that no other parts of the original report or attached press release have been modified.

Why did Proto Labs (PRLB) file an amendment to its February 6, 2026 8-K?

Proto Labs filed the amendment to fix a scrivener’s error in EPS guidance. The original exhibit misstated the Q1 2026 GAAP diluted EPS range, which is now clarified as $0.18–$0.26 in the amended filing.

Is Proto Labs’ corrected EPS guidance in the 8-K/A considered filed with the SEC?

The company notes that the information in Items 2.02 and 9.01, including the corrected guidance, is furnished rather than filed. It is therefore not subject to Section 18 liabilities or automatically incorporated into other SEC filings.